Literature DB >> 25739917

Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.

Holly E Humphries1, Charlotte Brookes2, Lauren Allen2, Eeva Kuisma2, Andrew Gorringe2, Stephen Taylor2.   

Abstract

The correlate of protection for the licensure of meningococcal vaccines is serum bactericidal activity. However, evidence indicates that a complex situation and other mechanisms, such as antibody-mediated, complement-dependent opsonophagocytosis (OP), may play a role in protection and should be investigated in order to understand immunity to this disease. In this study, a high-throughput flow cytometric opsonophagocytic assay (OPA) was optimized. The assay measures the presence of killed fluorescently labeled Neisseria meningitidis within human granulocytes (differentiated HL60 cells) by flow cytometry, using IgG-depleted pooled human plasma as an exogenous source of complement. This method was found to be reliable and correlated with the results of an opsonophagocytic killing assay. The OPA was used to measure OP activity in 1,878 serum samples from individuals ranging from 0 to 99 years of age against N. meningitidis strain NZ98/254 (B:4:P1.7-2,4). The levels of OP activity in individual serum samples varied greatly. OP activity showed an initial peak in the 6- to 12-month age group corresponding to a peak in disease incidence. The OP activity dropped in childhood until the late teenage years, although there was still a higher percentage of individuals with OP activity than with protective bactericidal antibody titers. OP activity reached a peak in the 30- to 39-year age group and then declined. This later peak in OP activity did not coincide with the young adults in whom peak serum bactericidal activity and disease incidence occurred. The demonstration of OP activity when disease incidence is low and when protective bactericidal antibody titers are not detected may indicate a role for OP in protection from meningococcal disease in these age groups.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25739917      PMCID: PMC4412933          DOI: 10.1128/CVI.00100-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

2.  Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay.

Authors:  C A Ison; N Anwar; M J Cole; R Galassini; R S Heyderman; N J Klein; J West; A J Pollard; S Morley; R e Levin and the Meningococcal
Journal:  Microb Pathog       Date:  1999-10       Impact factor: 3.738

3.  The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data.

Authors:  G F Reed; B D Meade; M C Steinhoff
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

4.  Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals.

Authors:  A E Platonov; E J Kuijper; I V Vershinina; G A Shipulin; N Westerdaal; C A Fijen; J G van de Winkel
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  Functional assays for evaluation of serogroup B meningococcal structures as mediators of human opsonophagocytosis.

Authors:  A K Lehmann; A Halstensen; J Holst; C F Bassøe
Journal:  J Immunol Methods       Date:  1997-01-15       Impact factor: 2.303

6.  Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.

Authors:  Branda T Hu; Xinhong Yu; Thomas R Jones; Carol Kirch; Sarah Harris; Stephen W Hildreth; Dace V Madore; Sally A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

7.  Whole blood model of meningococcal bacteraemia--a method for exploring host-bacterial interactions.

Authors:  C A Ison; R S Heyderman; N J Klein; M Peakman; M Levin
Journal:  Microb Pathog       Date:  1995-02       Impact factor: 3.738

8.  Flow cytometric quantitation of human opsonin-dependent phagocytosis and oxidative burst responses to meningococcal antigens.

Authors:  A K Lehmann; A Halstensen; C F Bassøe
Journal:  Cytometry       Date:  1998-12-01

9.  Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine.

Authors:  Alexander E Platonov; Irina V Vershinina; Edward J Kuijper; Ray Borrow; Helena Käyhty
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

10.  Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.

Authors:  J Andreoni; H Käyhty; P Densen
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

View more
  3 in total

1.  The SaeRS Two-Component System Controls Survival of Staphylococcus aureus in Human Blood through Regulation of Coagulase.

Authors:  Haiyong Guo; Jeffrey W Hall; Junshu Yang; Yinduo Ji
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

2.  Cross-reactivity with Brazilian strains of Neisseria meningitidis B after immunization with outer membrane vesicles.

Authors:  Gabriela Trzewikoswki de Lima; Amanda Izeli Portilho; Elizabeth De Gaspari
Journal:  Ther Adv Vaccines Immunother       Date:  2019-12-11

3.  Development of flow cytometric opsonophagocytosis and antibody-mediated complement deposition assays for non-typeable Haemophilus influenzae.

Authors:  Stephen R Thomas; Stephanie Leung; Katy Knox; Tom M A Wilkinson; Karl J Staples; Pascal Lestrate; Dominique Wauters; Andrew Gorringe; Stephen C Taylor
Journal:  BMC Microbiol       Date:  2018-10-29       Impact factor: 3.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.